Clinical Trials Logo
  1. Home
  2. Hepatorenal Syndrome
  3. NCT02770716

Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

Hepatorenal Syndrome Clinical Trial

Official title:
A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study)

Clinical Trial Summary

This study is to treat adult patients with hepatorenal syndrome (HRS) Type 1. Out of every three participants, two will receive terlipressin and one will receive placebo. Assignments will be made randomly.

Clinical Trial Description

The primary objective of this trial is to confirm the efficacy and safety of intravenous terlipressin versus placebo in the treatment of adult subjects with hepatorenal syndrome (HRS) Type 1. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02770716
Study type Interventional
Source Mallinckrodt
Contact
Status Completed
Phase Phase 3
Start date July 13, 2016
Completion date July 24, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT00370253 - Noradrenalin vs Terlipressin in Hepatorenal Syndrome Phase 3
Completed NCT00359853 - Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Phase 4
Completed NCT01436500 - Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Phase 2
Completed NCT01143246 - A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Phase 3
Recruiting NCT05346393 - HRS-AKI Treatment With TIPS in Patients With Cirrhosis N/A
Terminated NCT00734136 - Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome N/A
Terminated NCT00742339 - Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Phase 2/Phase 3
Recruiting NCT06095440 - A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
Recruiting NCT06256432 - Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome Phase 2
Completed NCT02097784 - Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury N/A
Recruiting NCT04898010 - The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I N/A
Recruiting NCT05875948 - Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome Phase 2
Completed NCT04416282 - Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure. N/A
Recruiting NCT02049125 - Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis N/A
Completed NCT00764049 - Single Pass Albumin Dialysis in Patients With Cirrhosis Phase 1/Phase 2
Completed NCT00089570 - Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 Phase 3
Withdrawn NCT01587222 - Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Phase 2
Recruiting NCT02489864 - The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Phase 4
Recruiting NCT02434445 - Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients N/A
Completed NCT05387811 - International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project